$38B of manufacturing value, 71% of which is exports
2nd in Europe for pharmaceutical production
Italy exports 85% of the API it produces
42% of employees are women; 52% in R&D
40% of companies are Italian owned
Exports have grown 52% since 2010, the largest increase in Europe
Modena — Holoclar, the world's first stem cell therapy, was approved by the EMA in 2015 for patients with extreme corneal damage. It is manufactured by Holostem Advanced Therapies, a spinoff of the University of Modena.
Milan — The world's first ex vivo stem cell gene therapy based on Italian research and developed by GlaxoSmithKline in collaboration with Fondazione Telethon and Ospedale San Raffaele. Approved by the EMA in 2016, the treatment is for children with ADA-SCID, a rare disease also known as “bubble baby” disease.
Milan — The San Raffaele Scientific Institute of Milan, research partner to spinoff biotechnology company Gernenta, developing novel gene transfer cancer treatments.
Origgio — BioUpper provides support for innovation in the life sciences, giving startups access to biomedical resources, facilities, and experts. Partners include Novartis and the philanthropic Fondazione Cariplo.
Lazlo — One of the top ten EU regions for number of workers in the pharmaceutical industry and home to Lazio Innova, a cluster of universities, hospitals, IT, and biopharmaceutical companies.
Lombardy — With 46,000 employees, this is another of the EU's top ten regions for pharmaceutical workers. In addition, Italy has a robust program of clinical trials, half of which are conducted in Lombardy.
On 26–27 October 2019, the first Global Student & Young Professional Hackathon was held at the 2019 ISPE Annual Meeting & Expo. Thirty-six ISPE Young Professional and Student members came from around the world to participate in the two-day event that demonstrated innovative thinking, collaboration,...
The pharmaceutical industry is ever-changing, as we saw demonstrated during the 2019 ISPE Annual Meeting & Expo, and at other ISPE conferences around the world. In fact, change is accelerating—and to support the trends and developments in the industry, ISPE has developed a new three-year Strategic...
As I sit at my computer to write my first column as ISPE International Board Chair, my thoughts are centered on how I can personally help drive our unifying vision, “Connecting Pharmaceutical Knowledge,” and how we as members of ISPE have an outstanding opportunity in the year ahead to provide...